Medicare has introduced a more constrained method of paying for services for end-stage renal disease (ESRD) — bundling together most dialysis services and establishing a fixed compensation amount for them, reducing incentives for overuse of drugs such as ESAs.
No takes yet. Share an insight, caveat, or question.
John K. Iglehart (2011) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: